evidence: The IRA is a mix of constructive and counterproductive reforms. Reforming insurance to lower out-of-pocket costs for patients makes sense. Subjecting biologics to price controls 13 years after they launch will help ensure that these types of medicines, which do not lend themselves to the same genericization process that renders small molecules inexpensive after patent expiration, abide by the intent of the patent system to see old inventions drop in price. But the aggressive price controlling of small molecule and other drugs approved via the NDA regulatory pathway just 9 years after they launch does not fix any market failure but rather breaks what is already working and therefore merits a rethink.